GTCB 's strategic alliance could be the most important development in GTCB's history......
New bioceuticals (protein based) are usally not initially developed by big pharma. They are usually taken thru pre clinicals to phase2 by small or mid size biotechs. This requires only a relative small amount of the desired bioceutical and the biotechs outsource this to companies like Laureate who specialise in providing the new product. Historically they have used cell culture. This has caused a huge roadblock to GTCB's transgenic platform, because once the companies start to produce the protein by cell culture FDA rules make it virtually impossible to move to transgenics. Forming an alliance with Laureate will allow GTCB to enter the production pipeline mainstream something that has hindered it in the past...........THIS IS HUGE